HK1092151A1 - Polymorphous forms of rifaximin as antibiotics - Google Patents

Polymorphous forms of rifaximin as antibiotics

Info

Publication number
HK1092151A1
HK1092151A1 HK06113864.0A HK06113864A HK1092151A1 HK 1092151 A1 HK1092151 A1 HK 1092151A1 HK 06113864 A HK06113864 A HK 06113864A HK 1092151 A1 HK1092151 A1 HK 1092151A1
Authority
HK
Hong Kong
Prior art keywords
rifaximin
antibiotics
polymorphous forms
polymorphous
forms
Prior art date
Application number
HK06113864.0A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1092151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Priority to HK06113864.0A priority Critical patent/HK1092151A1/xx
Publication of HK1092151A1 publication Critical patent/HK1092151A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK06113864.0A 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics HK1092151A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics

Publications (1)

Publication Number Publication Date
HK1092151A1 true HK1092151A1 (en) 2007-02-02

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06113863.1A HK1092150A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK06113863.1A HK1092150A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic

Country Status (38)

Country Link
US (5) US7045620B2 (xx)
EP (6) EP1557421B1 (xx)
JP (5) JP2005139161A (xx)
KR (4) KR20050043589A (xx)
CN (4) CN1613858A (xx)
AR (3) AR043547A1 (xx)
AT (3) ATE421966T1 (xx)
AU (2) AU2004200964A1 (xx)
BR (2) BRPI0402382A (xx)
CA (2) CA2460384A1 (xx)
CL (1) CL2004000498A1 (xx)
CO (1) CO5560083A1 (xx)
CY (3) CY1108017T1 (xx)
DE (4) DE602004006367C5 (xx)
DK (3) DK1557421T3 (xx)
ES (3) ES2320161T3 (xx)
HK (3) HK1092150A1 (xx)
HR (2) HRP20040265A2 (xx)
IL (2) IL160798A0 (xx)
IT (1) ITMI20032144A1 (xx)
JO (1) JO2470B1 (xx)
MA (1) MA27069A1 (xx)
MD (1) MD3653G8 (xx)
ME (1) ME00424B (xx)
MX (2) MXPA04002353A (xx)
NO (1) NO334950B1 (xx)
NZ (1) NZ531622A (xx)
PL (3) PL1557421T3 (xx)
PT (3) PT1557421E (xx)
RS (4) RS54571B1 (xx)
RU (1) RU2270200C2 (xx)
SI (3) SI1557421T1 (xx)
TN (2) TNSN04044A1 (xx)
TW (1) TWI285107B (xx)
UA (1) UA86384C2 (xx)
WO (1) WO2005044823A2 (xx)
YU (1) YU24804A (xx)
ZA (1) ZA200401948B (xx)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
DK1698630T3 (da) * 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2659874C (en) 2006-08-02 2016-10-11 Salix Pharmaceuticals, Inc. Methods for the treatment of radiation proctosigmoiditis
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) * 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
PL2252148T3 (pl) * 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
DK2294012T3 (da) 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
ES2496190T3 (es) 2008-09-26 2014-09-18 Aska Pharmaceutical Co., Ltd. Agente profiláctico y/o terapéutico para trastornos gastrointestinales funcionales
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
SI3628319T1 (sl) 2008-10-02 2024-04-30 Salix Pharmaceuticals, Ltd. Zdravljenje jetrne encefalopatije z rifaksiminom
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
NZ596851A (en) * 2009-06-02 2013-10-25 Salix Pharmaceuticals Ltd Methods of treating hepatic encephalopathy
KR20120062897A (ko) 2009-09-13 2012-06-14 샐릭스 파마슈티컬스 리미티드 과민성 장 증후군(ｉｂｓ)의 치료방법
KR20200100215A (ko) * 2009-10-27 2020-08-25 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
BR112012012316A2 (pt) 2009-11-23 2016-04-26 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou ânus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de um silicone e dispensador para composição farmacêutica
WO2011080691A1 (en) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800668A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
CN103228662B (zh) 2010-07-12 2016-08-10 萨利克斯药品有限公司 利福昔明的制剂及其用途
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
US8735419B2 (en) * 2011-02-11 2014-05-27 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
AU2012332211B2 (en) * 2011-11-02 2016-11-24 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
JP6433980B2 (ja) 2013-04-12 2018-12-05 アルファシグマ ソシエタ ペル アチオニ Ｎｓａｉｄ投与並びに関連する組成物、方法及びシステム
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2946101A1 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
PL3434265T3 (pl) 2016-03-24 2021-12-13 Sandoz Ag Kompozycja farmaceutyczna zawierająca rifaksyminę alfa i delta
US10842782B2 (en) 2016-03-24 2020-11-24 Sandoz Ag Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018064472A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Ltd. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
US20220378758A1 (en) 2019-09-24 2022-12-01 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ATE125541T1 (de) * 1990-06-29 1995-08-15 Lepetit Spa Reine kristalline form von rifapentin.
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100338028C (zh) * 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Also Published As

Publication number Publication date
CY1108964T1 (el) 2014-07-02
KR20070113326A (ko) 2007-11-28
EP2210893A1 (en) 2010-07-28
BRPI0407149A (pt) 2006-02-07
MXPA04002353A (es) 2005-05-11
ATE421966T1 (de) 2009-02-15
US8173801B2 (en) 2012-05-08
JP2007509904A (ja) 2007-04-19
WO2005044823A3 (en) 2005-10-27
ES2320161T3 (es) 2009-05-19
RU2004108953A (ru) 2005-10-27
EP1676848A1 (en) 2006-07-05
MA27069A1 (fr) 2004-12-20
ES2320160T4 (es) 2011-03-09
ATE361927T1 (de) 2007-06-15
SI1676847T1 (sl) 2009-06-30
NO334950B1 (no) 2014-08-04
ZA200401948B (en) 2004-04-29
BRPI0402382A (pt) 2005-06-28
MXPA06002644A (es) 2006-06-06
DE602004019298D1 (de) 2009-03-19
CN101260115B (zh) 2011-11-23
CY1108909T1 (el) 2014-07-02
CA2538546A1 (en) 2005-05-19
CN1613858A (zh) 2005-05-11
US20120059023A1 (en) 2012-03-08
CA2538546C (en) 2011-04-19
PL1676847T3 (pl) 2009-07-31
EP1676848B1 (en) 2009-01-28
BRPI0407149A8 (pt) 2019-01-15
MD3653G8 (ro) 2016-08-31
US20110160449A1 (en) 2011-06-30
IL160798A0 (en) 2004-08-31
PL1676848T3 (pl) 2009-07-31
PL1557421T3 (pl) 2007-08-31
RS54568B1 (en) 2016-06-30
RS20150292A1 (xx) 2015-10-30
KR100855084B1 (ko) 2008-08-29
CN1886408A (zh) 2006-12-27
SI1557421T1 (sl) 2007-08-31
KR100883216B1 (ko) 2009-02-13
CO5560083A1 (es) 2005-09-30
RS54569B1 (en) 2016-06-30
JP5199576B2 (ja) 2013-05-15
JP2011046738A (ja) 2011-03-10
ITMI20032144A1 (it) 2005-05-08
AU2004287601B2 (en) 2009-02-26
AU2004200964A1 (en) 2005-05-26
ME00424B (me) 2011-10-10
DE602004006367T2 (de) 2007-09-06
TWI285107B (en) 2007-08-11
HRP20060093B1 (hr) 2015-12-18
HK1073657A1 (en) 2005-10-14
ES2244364T3 (es) 2007-12-01
DE04005541T1 (de) 2005-12-29
MD3653F2 (en) 2008-07-31
KR20070113327A (ko) 2007-11-28
JO2470B1 (en) 2009-01-20
IL174271A0 (en) 2006-08-01
US7045620B2 (en) 2006-05-16
SI1676848T1 (sl) 2009-06-30
CL2004000498A1 (es) 2005-03-11
EP1557421B1 (en) 2007-05-09
RS20150291A1 (xx) 2015-10-30
DE602004006367C5 (de) 2019-04-04
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
CY1108017T1 (el) 2013-09-04
RS54571B1 (en) 2016-06-30
EP1676847B1 (en) 2009-01-28
DK1676848T3 (da) 2009-05-11
RU2270200C2 (ru) 2006-02-20
NO20061110L (no) 2006-04-19
DE602004006367D1 (de) 2007-06-21
NZ531622A (en) 2004-10-29
US20050272754A1 (en) 2005-12-08
CN1886408B (zh) 2010-06-09
CN101260115A (zh) 2008-09-10
DE602004019296D1 (de) 2009-03-19
IL174271A (en) 2010-12-30
ES2244364T1 (es) 2005-12-16
KR100867751B1 (ko) 2008-11-10
KR20050043589A (ko) 2005-05-11
DK1676847T3 (da) 2009-05-11
TNSN04044A1 (en) 2006-06-01
PT1676848E (pt) 2009-04-09
MD20060080A (en) 2006-11-30
PT1676847E (pt) 2009-04-09
JP5635376B2 (ja) 2014-12-03
US8404704B2 (en) 2013-03-26
AR081991A2 (es) 2012-10-31
US7915275B2 (en) 2011-03-29
US20080132530A1 (en) 2008-06-05
JP2014177500A (ja) 2014-09-25
EP1676847A1 (en) 2006-07-05
CA2460384A1 (en) 2005-05-07
CN101260114A (zh) 2008-09-10
UA86384C2 (uk) 2009-04-27
KR20060110737A (ko) 2006-10-25
EP1557421A1 (en) 2005-07-27
YU24804A (sh) 2006-08-17
US20050101598A1 (en) 2005-05-12
ATE421965T1 (de) 2009-02-15
AR043547A1 (es) 2005-08-03
DK1557421T3 (da) 2007-09-17
AU2004287601B8 (en) 2009-03-05
HK1092150A1 (en) 2007-02-02
RS20060168A (xx) 2008-09-29
CN101260114B (zh) 2012-11-28
EP1682556A2 (en) 2006-07-26
JP2011057698A (ja) 2011-03-24
HRP20060093A2 (en) 2006-05-31
TNSN06069A1 (en) 2007-10-03
AR081992A2 (es) 2012-10-31
JP2005139161A (ja) 2005-06-02
AU2004287601A1 (en) 2005-05-19
PT1557421E (pt) 2007-07-31
TW200515913A (en) 2005-05-16
WO2005044823A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
HK1092150A1 (en) Polymorphous forms of rifaximin as antibiotics
HK1093483A1 (en) Polymorphic form of n-
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
GB0304424D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
EP1648885A4 (en) NEW CONNECTIONS
EP1487414A4 (en) ANTIBIOTIC COMPOSITION
EP1620101A4 (en) POLYMORPHS OF CABERGOLIN
ZA200507475B (en) Derivatives of azithromycin
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0315629D0 (en) New uses for antibiotic
EP1793812A4 (en) ANTIBIOTIC COMPOUND
GB0302546D0 (en) Novel compounds
EP1756034A4 (en) ANTIBIOTIC COMPOUND
EP1635834A4 (en) NEW COMPOUNDS
GB0302008D0 (en) Antibiotic derivatives
PL378080A1 (pl) Sposób wytwarzania K-252A
GB0303767D0 (en) Gentamycin antibiotics
GB0303874D0 (en) Novel antibacterial compounds
TW568246U (en) Gasifying kiln
PL114147U1 (en) Interior decoration element
GB0301480D0 (en) Novel compounds
GB0301589D0 (en) Novel compounds
GB0300484D0 (en) Novel compounds
GB0300483D0 (en) Novel compounds

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240308